Susquehanna International Group’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-11,000
| Closed | -$17.3K | – | 13044 |
|
|
2024
Q3 | $17.3K | Sell |
11,000
-15,000
| -58% | -$24.8K | ﹤0.01% | 11655 |
|
|
2024
Q2 | $46.5K | Buy |
+26,000
| New | +$60.3K | ﹤0.01% | 11440 |
|
|
2021
Q4 | – | Sell |
-23,670
| Closed | -$163K | – | 13777 |
|
|
2021
Q3 | $163K | Sell |
23,670
-2,450
| -9% | -$17.9K | ﹤0.01% | 11720 |
|
|
2021
Q2 | $212K | Buy |
26,120
+19,590
| +300% | +$219K | ﹤0.01% | 11482 |
|
|
2021
Q1 | $102K | Buy |
6,530
+4,820
| +282% | +$71.4K | ﹤0.01% | 11854 |
|
|
2020
Q4 | $23K | Buy |
+1,710
| New | +$12.6K | ﹤0.01% | 10871 |
|
|
2016
Q3 | – | Sell |
-376
| Closed | -$130K | – | 8923 |
|
|
2016
Q2 | $130K | Sell |
376
-78
| -17% | -$55.9K | ﹤0.01% | 7896 |
|
|
2016
Q1 | $378K | Buy |
454
+362
| +393% | +$288K | ﹤0.01% | 6866 |
|
|
2015
Q4 | $96K | Sell |
92
-2,422
| -96% | -$2.43M | ﹤0.01% | 8901 |
|
|
2015
Q3 | $1.97M | Buy |
2,514
+1,656
| +193% | +$1.7M | ﹤0.01% | 4314 |
|
|
2015
Q2 | $1.13M | Sell |
858
-235
| -22% | -$379K | ﹤0.01% | 5948 |
|
|
2015
Q1 | $2.22M | Buy |
1,093
+453
| +71% | +$984K | ﹤0.01% | 4127 |
|
|
2014
Q4 | $1.23M | Buy |
+640
| New | +$1.14M | ﹤0.01% | 5447 |
|
Other funds holding RGLS
Susquehanna International Group's RGLS Position: Q2 2025 in Review
Susquehanna International Group sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 150,813 shares — an estimated $264K sold.
Susquehanna International Group first reported a position in RGLS in Q4 2014 and held it in 22 quarters. The position peaked at $2.5M in Q3 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Susquehanna International Group reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 150,813 Regulus Therapeutics shares in Q2 2025, an estimated $264K.
- Susquehanna International Group first reported a position in Regulus Therapeutics in Q4 2014 and held it in 22 quarters.
- Susquehanna International Group's Regulus Therapeutics position peaked at $2.5M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.